FDA warned Villas Health over website claims for compounded semaglutide and sildenafil, calling the drugs misbranded and unapproved.
What happened
In August 2025, FDA reviewed the website https://villashealth.com and found it offered compounded semaglutide and sildenafil. FDA said the site’s claims compared these compounded drugs to Ozempic, Wegovy, and Viagra, making them misbranded because compounded drugs are not FDA-approved. No inspection was reported.
What FDA found
FDA says the website claim that compounded semaglutide contains the same active ingredient as Ozempic and Wegovy misleadingly implies it is the same as FDA-approved products.
FDCA section 502(a) [21 U.S.C. § 352(a)]; section 502(bb) [21 U.S.C. § 352(bb)]FDA says the website claim that sildenafil is the active ingredient in Viagra and is clinically proven for sexual arousal disorder in women is false or misleading.
FDCA section 502(a) [21 U.S.C. § 352(a)]; section 502(bb) [21 U.S.C. § 352(bb)]FDA says compounded drugs are not FDA-approved, so claims implying equivalence to approved products misbrand them.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)]FDA says introducing these misbranded products into interstate commerce is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA says receiving misbranded drugs in interstate commerce and delivering them is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Villas Health to stop using the misleading claims immediately and to send a written response within 15 working days describing corrective steps, how it will prevent recurrence, and supporting documents.
Who should pay attention
- telehealth companies selling compounded drugs
- compounding pharmacies with consumer-facing websites
- online pharmacies and drug marketing agencies
This is a summary. Read the original letter on fda.gov.